Price Chart

Profile

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
URL https://www.altimmune.com
Investor Relations URL https://ir.altimmune.com/
HQ State/Province Maryland
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 08, 2025 (est.)
Last Earnings Release May. 08, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jan. 20, 2017

Profile

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
URL https://www.altimmune.com
Investor Relations URL https://ir.altimmune.com/
HQ State/Province Maryland
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 08, 2025 (est.)
Last Earnings Release May. 08, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jan. 20, 2017